Programme AnalyticsGLP-1 real-world evidence dashboard
De-identified, aggregated cohort data · semaglutide connected-care programme · Predictive Metabolic Intelligence™ · Last 12 months
Total enrolled
2,400
↑ 300 this month
Currently active
1,962
82% of enrolled
12-mo persistence
54%
↑ vs 23% category norm
Discontinued
1,312
37% GI-related
Avg TIR gain
+19%
across all doses
Avg weight change
−6.2 kg
↓ at 6 months
Enrolment & active cohort
New sign-ups vs cumulative active members · last 12 months
Retention & drop-off curve
% still on therapy by week — the titration cliff is weeks 4–12
Dose distribution
Where members sit on the titration ladder
32% never progress past 0.5 mg — the biggest titration bottleneck.
Why members discontinue
1,312 discontinuations · captured from in-app member check-ins
GI side-effects486 · 37%
Cost / access328 · 25%
Plateau / low motivation249 · 19%
Reached goal157 · 12%
Clinical / other92 · 7%
37% leave over GI side-effects — concentrated in weeks 4–12. Targeted support here is the single biggest retention lever.
Adherence mix
% of doses taken on schedule
High (>90%)44%
Medium (70–90%)33%
Low (<70%)23%
6-month outcome trends — on programme vs pre-programme baseline
Members with ≥6 months of pre-programme data (n = 842) · dashed = pre-period baseline
Pre-programme members were flat across 6 months (glucose 132→133, TIR 54→53%). On programme, the same cohort moved to 109 mg/dL and 82% TIR — the separation is the programme effect.
Pre vs post — 6-month summary
Matched cohort, paired comparison
Measure
Pre
6 mo
Change
Avg glucose
133 mg/dL
109 mg/dL
−24
Time in range
53%
82%
+29 pts
Body weight
94.3 kg
87.6 kg
−6.7 kg
Glycaemic variability
38%
24%
−14 pts
Sleep efficiency
78%
86%
+8 pts
Overnight HRV
34 ms
41 ms
+7 ms
12-month persistence
23%
54%
+31 pts
Pre-period sourced from members with prior CGM/clinical records. Where no pre-period exists, members are excluded from this comparison and shown in the cohort trends only.
Improvement by dose cohort
Time-in-range gain and weight loss at 6 months
Clear dose-response: members reaching 2.4 mg gain +28% TIR vs +11% at 0.5 mg — reinforcing the value of completing titration.
Performance by site
Enrolment, retention and outcome by city
Site
Enrolled
Retention
TIR gain
Mumbai
612
71%
+21%
Delhi NCR
548
64%
+18%
Bengaluru
431
69%
+20%
Hyderabad
366
58%
+15%
Pune
288
73%
+23%
Chennai
259
61%
+17%
Pune leads on retention (73%) — its onboarding protocol is worth replicating at Hyderabad (58%).
All figures are de-identified and aggregated; no individual member is identifiable. Glucose derived from aabo LinX CGM and aaboRing NGM. Real-world evidence for programme monitoring — not a substitute for clinical trial data.